S&P 500   3,324.95 (-0.08%)
DOW   27,230.87 (+0.11%)
QQQ   271.53 (+0.18%)
AAPL   446.48 (+1.42%)
MSFT   213.04 (+0.04%)
FB   260.89 (+4.72%)
GOOGL   1,488.00 (+0.60%)
AMZN   3,192.90 (-0.38%)
NVDA   449.46 (-0.45%)
CGC   18.39 (-4.27%)
BABA   260.37 (-1.72%)
TSLA   1,490.01 (+0.34%)
MU   48.73 (-4.55%)
GE   6.33 (-1.09%)
AMD   85.94 (+0.74%)
T   29.81 (-0.13%)
F   6.95 (-0.14%)
ACB   10.28 (-4.11%)
GILD   68.77 (-0.33%)
NFLX   502.98 (+0.17%)
DIS   127.47 (-0.11%)
BAC   25.47 (+0.28%)
BA   172.81 (-0.84%)
S&P 500   3,324.95 (-0.08%)
DOW   27,230.87 (+0.11%)
QQQ   271.53 (+0.18%)
AAPL   446.48 (+1.42%)
MSFT   213.04 (+0.04%)
FB   260.89 (+4.72%)
GOOGL   1,488.00 (+0.60%)
AMZN   3,192.90 (-0.38%)
NVDA   449.46 (-0.45%)
CGC   18.39 (-4.27%)
BABA   260.37 (-1.72%)
TSLA   1,490.01 (+0.34%)
MU   48.73 (-4.55%)
GE   6.33 (-1.09%)
AMD   85.94 (+0.74%)
T   29.81 (-0.13%)
F   6.95 (-0.14%)
ACB   10.28 (-4.11%)
GILD   68.77 (-0.33%)
NFLX   502.98 (+0.17%)
DIS   127.47 (-0.11%)
BAC   25.47 (+0.28%)
BA   172.81 (-0.84%)
S&P 500   3,324.95 (-0.08%)
DOW   27,230.87 (+0.11%)
QQQ   271.53 (+0.18%)
AAPL   446.48 (+1.42%)
MSFT   213.04 (+0.04%)
FB   260.89 (+4.72%)
GOOGL   1,488.00 (+0.60%)
AMZN   3,192.90 (-0.38%)
NVDA   449.46 (-0.45%)
CGC   18.39 (-4.27%)
BABA   260.37 (-1.72%)
TSLA   1,490.01 (+0.34%)
MU   48.73 (-4.55%)
GE   6.33 (-1.09%)
AMD   85.94 (+0.74%)
T   29.81 (-0.13%)
F   6.95 (-0.14%)
ACB   10.28 (-4.11%)
GILD   68.77 (-0.33%)
NFLX   502.98 (+0.17%)
DIS   127.47 (-0.11%)
BAC   25.47 (+0.28%)
BA   172.81 (-0.84%)
S&P 500   3,324.95 (-0.08%)
DOW   27,230.87 (+0.11%)
QQQ   271.53 (+0.18%)
AAPL   446.48 (+1.42%)
MSFT   213.04 (+0.04%)
FB   260.89 (+4.72%)
GOOGL   1,488.00 (+0.60%)
AMZN   3,192.90 (-0.38%)
NVDA   449.46 (-0.45%)
CGC   18.39 (-4.27%)
BABA   260.37 (-1.72%)
TSLA   1,490.01 (+0.34%)
MU   48.73 (-4.55%)
GE   6.33 (-1.09%)
AMD   85.94 (+0.74%)
T   29.81 (-0.13%)
F   6.95 (-0.14%)
ACB   10.28 (-4.11%)
GILD   68.77 (-0.33%)
NFLX   502.98 (+0.17%)
DIS   127.47 (-0.11%)
BAC   25.47 (+0.28%)
BA   172.81 (-0.84%)
Log in

NASDAQ:BLRXBIOLINERX LTD/S Stock Price, Forecast & News

$2.00
-0.35 (-14.89 %)
(As of 08/6/2020 12:02 PM ET)
Add
Compare
Today's Range
$1.89
Now: $2.00
$2.22
50-Day Range
$1.62
MA: $1.87
$2.37
52-Week Range
$1.06
Now: $2.00
$4.08
Volume8,465 shs
Average Volume530,601 shs
Market Capitalization$14.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is based in Modi'in, Israel.
Read More
BIOLINERX LTD/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.77 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-8642-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.46 per share

Profitability

Net Income$-25,450,000.00

Miscellaneous

Employees51
Market Cap$14.96 million
Next Earnings Date8/6/2020 (Confirmed)
OptionableNot Optionable
$2.00
-0.35 (-14.89 %)
(As of 08/6/2020 12:02 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BIOLINERX LTD/S (NASDAQ:BLRX) Frequently Asked Questions

How has BIOLINERX LTD/S's stock been impacted by COVID-19 (Coronavirus)?

BIOLINERX LTD/S's stock was trading at $1.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BLRX stock has increased by 25.0% and is now trading at $2.00.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of BIOLINERX LTD/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BIOLINERX LTD/S
.

When is BIOLINERX LTD/S's next earnings date?

BIOLINERX LTD/S is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for BIOLINERX LTD/S
.

How were BIOLINERX LTD/S's earnings last quarter?

BIOLINERX LTD/S (NASDAQ:BLRX) issued its earnings results on Wednesday, May, 20th. The biotechnology company reported ($0.60) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.83) by $0.23.
View BIOLINERX LTD/S's earnings history
.

What price target have analysts set for BLRX?

1 Wall Street analysts have issued 1 year price objectives for BIOLINERX LTD/S's stock. Their forecasts range from $11.00 to $18.00. On average, they anticipate BIOLINERX LTD/S's stock price to reach $14.50 in the next year. This suggests a possible upside of 625.0% from the stock's current price.
View analysts' price targets for BIOLINERX LTD/S
.

Has BIOLINERX LTD/S been receiving favorable news coverage?

Press coverage about BLRX stock has been trending negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIOLINERX LTD/S earned a news impact score of -2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about BIOLINERX LTD/S
.

Who are some of BIOLINERX LTD/S's key competitors?

What other stocks do shareholders of BIOLINERX LTD/S own?

Who are BIOLINERX LTD/S's key executives?

BIOLINERX LTD/S's management team includes the following people:
  • Mr. Philip A. Serlin CPA, MBA, Chief Exec. Officer (Age 59)
  • Ms. Mali Zeevi CPA, Chief Financial Officer (Age 43)
  • Dr. Ella Sorani, VP R&D (Age 51)
  • Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 44)
  • Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 67)

What is BIOLINERX LTD/S's stock symbol?

BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX."

Who are BIOLINERX LTD/S's major shareholders?

BIOLINERX LTD/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Psagot Investment House Ltd. (1.56%).

Which institutional investors are buying BIOLINERX LTD/S stock?

BLRX stock was bought by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd..

How do I buy shares of BIOLINERX LTD/S?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BIOLINERX LTD/S's stock price today?

One share of BLRX stock can currently be purchased for approximately $2.00.

How big of a company is BIOLINERX LTD/S?

BIOLINERX LTD/S has a market capitalization of $14.96 million. The biotechnology company earns $-25,450,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. BIOLINERX LTD/S employs 51 workers across the globe.

What is BIOLINERX LTD/S's official website?

The official website for BIOLINERX LTD/S is www.biolinerx.com.

How can I contact BIOLINERX LTD/S?

BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.